SCHEMBL7591535

SCHEMBL7591535

CCCSc1nc(N)nc2c1ncn2CCOCP(=O)(O)O

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 4/20 0.57
CYP2C19 P33261 2/20 0.55
FGFR1 P11362 3/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
POLB P06746 4/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
CYP2C9 P11712 1/20 0.48
HIF1A Q16665 1/20 0.48
POLA1 P09884 1/20 0.44
POLG P54098 1/20 0.44
HPRT1 P00492 3/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNE1 P24864 1/20 0.41
CDK2 P24941 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12149448 0.84 SLC29A1 (0.51) SLC29A1CYP2C19FGFR1SLC22A6POLB
SCHEMBL7591540 0.84 SLC29A1 (0.63) SLC29A1CYP2C19POLBCYP1A2CYP3A4
SCHEMBL1565558 0.82 FGFR1 (0.57) CYP2C19FGFR1SLC22A6POLBPOLA1
SCHEMBL7128447 0.82 FGFR1 (0.48) SLC29A1CYP2C19FGFR1SLC22A6POLB
SCHEMBL7119964 0.82 FGFR1 (0.48) SLC29A1CYP2C19FGFR1SLC22A6POLB
SCHEMBL2607253 0.82 SLC22A6 (0.62) CYP2C19FGFR1SLC22A6POLBPOLA1
Pmedap SCHEMBL29571667 0.81 FGFR1 (0.72) FGFR1SLC22A6POLBCYP3A4POLA1
Pmedap SCHEMBL215611 0.81 FGFR1 (0.72) FGFR1SLC22A6POLBCYP3A4POLA1
SCHEMBL1565553 0.81 FGFR1 (0.56) CYP2C19FGFR1SLC22A6POLBPOLA1
SCHEMBL1567264 0.81 FGFR1 (0.58) CYP2C19FGFR1SLC22A6POLBPOLA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 US disclosed
US-9139604-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2015-09-22 US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 US disclosed
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2015-01-22 US disclosed
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 US disclosed
US-8871785-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2014-10-28 US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 US disclosed
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. (US) 2011-11-24 US disclosed
US-8022083-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2011-09-20 US disclosed
US-8022083-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2011-09-20 US disclosed
US-20110071101-A1 Nucleoside Phosphonate Analogs BOOJAMRA CONSTANTINE G 2011-03-24 US disclosed
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2009-11-05 US disclosed
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS GILEAD SCIENCES, INC. 2009-11-05 US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 US disclosed
US-7429565-B2 Antiviral phosphonate analogs GILEAD SCIENCES, INC. (US) 2008-09-30 US disclosed
EP-0919562-B1 PHOSPHONATE NUCLEOTIDE COMPOUNDS MITSUBISHI CHEM CORP (JP) 2002-11-06 EP disclosed
US-6194398-B1 VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS, HERPES SIMPLEX VIRUS, HEPATITIS B VIRUS; ANTITUMOR AGENTS; SIDE EFFECT REDUCTION; ORAL ABSORPTION BIOAVAILABILITY; A 2-AMINO-6-HYDROCARBYLTHIO-9-(2-(PHOSPHONOMETHOXY)ETHYL-9H-PURINE MITSUBISHI CHEMICAL CORPORATION (JP) 2001-02-27 US disclosed
EP-0919562-A1 PHOSPHONATE NUCLEOTIDE COMPOUNDS MITSUBISHI CHEMICAL CORPORATION (JP) 1999-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150025039-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP SLC29A1 113/4885CYP2C19 4055/4885FGFR1 3513/4885
US-20110071101-A1 Nucleoside Phosphonate Analogs TYMP, PNP, NUDT1 SLC29A1 8/4885CYP2C19 2247/4885FGFR1 2035/4885
US-20110288053-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP SLC29A1 113/4885CYP2C19 4055/4885FGFR1 3513/4885
US-20090275535-A1 ANTIVIRAL PHOSPHONATE ANALOGS TYMP, ITPA, PNP SLC29A1 113/4885CYP2C19 4055/4885FGFR1 3513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.